BMS-986405

Overview

JSMD194 (formerly LY3039478) is a small molecule Gamma-Secretase Inhibitor being investigated in clinical trials in patients with T-cell acute lymphoblastic leukemia, T-cell lymphoblastic lymphoma and multiple myeloma.

SparkCures ID 313
Developed By Eli Lilly and Company
Generic Name BMS-986405
Additional Names LY3039478, JSMD194
Treatment Classifications
  • Gamma-Secretase Inhibitor

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persiste...
View Trial
Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Verified
A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma
View Trial

SparkCures Verified Accurate, up-to-date information. Learn more

BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persiste...
View Trial
Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)

Resources

There are no resources, links or videos to display for this treatment.